Abstract: The invention provides a compound effective as an antitumor active agent or vaccine adjuvant and an intermediate useful for the synthesis of the compound, as well as production methods thereof, and a medicament containing the novel compound. The compound is a carbamate glycolipid represented by the formula (I) wherein each symbol is as defined herein. The invention also provides a dendritic cell pulsed with the glycolipid.

Abstract: The invention provides a compound represented by the formula (I) wherein R1 is a hydrogen atom or a hydroxyl group; two R2 are the same or different and each is a hydrogen atom or a hydroxyl group; R3 is a hydrocarbon group having 8-14 carbon atoms, which optionally has substituent(s); and R4 is a hydrocarbon group having 18-24 carbon atoms, which optionally has substituent(s), or a salt thereof. The invention also provides a method of treating an autoimmune disease or suppressing immunity by administering the aforementioned compound or a salt thereof to a patient in need thereof.

Abstract: The invention provides a compound represented by the formula (I) wherein R1 is a hydrogen atom or a hydroxyl group; two R2 are the same or different and each is a hydrogen atom or a hydroxyl group; R3 is a hydrocarbon group having 8-14 carbon atoms, which optionally has substituent(s); and R4 is a hydrocarbon group having 18-24 carbon atoms, which optionally has substituent(s), or a salt thereof. The invention also provides a method of treating an autoimmune disease or suppressing immunity by administering the aforementioned compound or a salt thereof to a patient in need thereof.

Abstract: The invention provides a compound effective as an antitumor active agent or vaccine adjuvant and an intermediate useful for the synthesis of the compound, as well as production methods thereof, and a medicament containing the novel compound. The compound is a carbamate glycolipid represented by the formula (I) wherein each symbol is as defined herein. The invention also provides a dendritic cell pulsed with the glycolipid.

Abstract: A compound represented by the following formula (1): wherein R1 is an aldopyranose residue wherein the 6-hydroxyl group is optionally alkylated, R2 is a C1-26 hydrocarbon group optionally having substituent(s), R3 is a hydrogen atom or a C1-26 hydrocarbon group optionally having substituent(s), R4 is a C1-21 hydrocarbon group optionally having substituent(s), X is an oxygen atom or —CH2—, and Y is —CH2—, —CH(OH)— or —CH?CH—, or a salt thereof is useful for the prophylaxis or treatment of cancer or infection, since it can preferentially induce production of IFN-? of NKT cells.

Abstract: The invention provides esterified ?-galactosylceramides effective for cancer treatment and the like, and a medicament containing same. In particular, the invention relates to a compound represented by the formula (I): wherein R1 is a hydrocarbon group having a carbon number of 1 to 30, R2 is a hydrocarbon group having a carbon number of 1 to 20, R3 is a hydrogen atom or hydrocarbon group having a carbon number of 1 to 5, R4 and R5 are the same or different and each is a hydrogen atom or a hydrocarbon group having a carbon number of 1 to 5, or R4 and R5 in combination form a divalent hydrocarbon group having a carbon number of 1 to 5, and optionally form a ring structure together with the adjacent ethylenedioxy, or a salt thereof.

Abstract: The invention provides a glycolipid effective for cancer treatment and the like and a synthetic intermediate therefor, as well as a medicament containing the glycolipid and the like.

Abstract: A compound represented by the following formula (1): wherein R1 is an aldopyranose residue wherein the 6-hydroxyl group is optionally alkylated, R2 is a C1-26 hydrocarbon group optionally having substituent(s), R3 is a hydrogen atom or a C1-26 hydrocarbon group optionally having substituent(s), R4 is a C1-21 hydrocarbon group optionally having substituent(s), X is an oxygen atom or —CH2—, and Y is —CH2—, —CH(OH)— or —CH?CH—, or a salt thereof is useful for the prophylaxis or treatment of cancer or infection, since it can preferentially induce production of IFN-? of NKT cells.

Abstract: The invention provides esterified ?-galactosylceramides effective for cancer treatment and the like, and a medicament containing same. In particular, the invention relates to a compound represented by the formula (I): wherein R1 is a hydrocarbon group having a carbon number of 1 to 30, R2 is a hydrocarbon group having a carbon number of 1 to 20, R3 is a hydrogen atom or hydrocarbon group having a carbon number of 1 to 5, R4 and R5 are the same or different and each is a hydrogen atom or a hydrocarbon group having a carbon number of 1 to 5, or R4 and R5 in combination form a divalent hydrocarbon group having a carbon number of 1 to 5, and optionally form a ring structure together with the adjacent ethylenedioxy, or a salt thereof.

Abstract: The invention provides a glycolipid effective for cancer treatment and the like and a synthetic intermediate therefor, as well as a medicament containing the glycolipid and the like.

Abstract: A compound having excellent macrophage activity inhibitory action, which is represented by the general following formula: wherein Q represents an oxygen atom, a C1-C3 alkylene group, a —O-Alk- group or a —O-Alk-O— group (in which Alk is a C1-C3 alkylene group), R1 represents a C1-C20 alkanoyl group which may be substituted, a C3-C20 alkenoyl group which may be substituted or a C3-C20 alkynoyl group which may be substituted, R2, R3 and R4, which may be the same or different, represent a hydrogen atom, a C1-C20 alkyl group which may be substituted, a C2-C20 alkenyl group which may be substituted, a C2-C20 alkynyl group which may be substituted, a C1-C20 alkanoyl group which may be substituted, a C3-C20 alkenoyl group which may be substituted or a C3-C20 alkynoyl group which may be substituted, R5 represents a hydrogen atom, a halogen atom, a hydroxyl group, a C1-C6 alkoxy group which may be substituted, a C2-C6 alkenyloxy group which may be substituted or a C2-C6 alkynyloxy group which may be substituted

Abstract: A compound of formula (I) below, which exhibits excellent macrophage activity inhibitory action, is useful for the treatment or prophylaxis of inflammatory disorders, autoimmune diseases or septicemia. In a preferred embodiment, R1 and R3 each represents a C1-C20 alkanoyl group which may optionally be substituted with one or more substituent groups selected from substituent group A, R2 and R4 each represents a C1-C20 alkyl group which may optionally be substituted with one or more substituent groups selected from substituent group A, R5 is a hydrogen atom, a halogen atom, a hydroxy group, or a C1-C6 alkoxy group, and substituent group A is a halogen atom, a hydroxy group, an oxo group, a C1-C20 alkoxy group, or a C1-C20 alkanoyloxy group.

Abstract: A compound of formula (I) below, which exhibits excellent macrophage activity inhibitory action, is useful for the treatment or prophylaxis of inflammatory disorders, autoimmune diseases or septicemia. In a preferred embodiment, R1 and R3 each represents a C1-C20 alkanoyl group which may optionally be substituted with one or more substituent groups selected from substituent group A, R2 and R4 each represents a C1-C20 alkyl group which may optionally be substituted with one or more substituent groups selected from substituent group A, R5 is a hydrogen atom, a halogen atom, a hydroxy group, or a C1-C6 alkoxy group, and substituent group A is a halogen atom, a hydroxy group, an oxo group, a C1-C20 alkoxy group, or a C1-C20 alkanoyloxy group.

Abstract: Compounds of formula (I): ##STR1## in which: R.sup.1 is hydroxy, protected hydroxy, fluorine, or --OP(O)(OH).sub.2 ; R.sup.2 and R.sup.3 are independently optionally substituted C.sub.6 -C.sub.20 aliphatic acyl; R.sup.4 is hydroxy, protected hydroxy, or --OP(O)(OH).sub.2, where at least one of R.sup.1 and R.sup.4 is --OP(O)(OH).sub.2 ; and R.sup.5 is hydroxy, protected hydroxy, or fluorine; provided that, except where at least one of R.sup.1 and R.sup.5 is fluorine, then at least one of R.sup.2 and R.sup.3 is a substituted C.sub.6 -C.sub.20 aliphatic acyl having (i) at least one halogen substituent and (ii) at least one substituent selected from the group consisting of halogen, hydroxy and C.sub.6 -C.sub.20 aliphatic acyloxy or at least one of R.sup.2 and R.sup.3 is a substituted C.sub.6 -C.sub.20 aliphatic acyl which is substituted by at least one halogen-substituted C.sub.6 -C.sub.